SNO 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Agencies, foundations and societies at SNO 2026

Nov 12–15, 2026 Philadelphia, PA ~3k attendees Website

19 agencies, foundations and societies are at SNO 2026 — 59 presentations on the program. Most represented: National Cancer Institute (12 on the program), National Institutes of Health (7 on the program), National Brain Tumor Society (4 on the program). 1 of them have their own page in this guide. As of Nov 12, 2026.

All 419 organizations at SNO 2026 →

Topic
Top represented
Showing 1–8 of 19 organizations
OrganizationSNO 2026 Attendance
Government agencies
A U.S. federal institute that supports cancer research and provides information on cancer prevention, diagnosis, and treatment.
Plenary
Fri Nov 13
9:50–10am
Part of Plenary I
SYSTEMIC INFLAMMATORY PROFILES ARE ASSOCIATED WITH PHYSICAL FUNCTIONAL IMPAIRMENT IN PRIMARY BRAIN TUMORS
Exhibit Hall C, Second Floor, Convention Center · Abstract NCOG-34
Survivorship
Talk
Fri Nov 13
12:15–12:18pm
Targeting Sphingolipid–Cholesterol Crosstalk as a Metabolic Vulnerability in IDH1-Mutant Glioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMET-04
Tumor biology
Talk
Fri Nov 13
12:27–12:30pm
SCD1 Inhibitor MF438 Drives Ferroptosis-Primed Lipidomic Reprogramming and Synergizes with Temozolomide in IDH-Mutant Glioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMET-05
Tumor biology
Poster
Fri Nov 13
7:30–9:30pm
Correlative analysis of anti-PD-1 immunotherapy in patients with recurrent IDH-mutant gliomas
Exhibit Hall D & E, Second Floor, Convention Center · Abstract BIOM-21
Biomarkers
Poster
Fri Nov 13
7:30–9:30pm
Phase I/II Trial of PLX038 in recurrent Primary CNS Tumors with and without MYC or MYCN Amplifications: results of the phase I study
Exhibit Hall D & E, Second Floor, Convention Center · Abstract CTNI-12
Trials
Poster
Fri Nov 13
7:30–9:30pm
Genome-wide CRISPR screen identifies PKMYT1 inhibition as a synthetic lethal vulnerability in IDH1-mutant glioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract DDDR-03
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Therapeutic targeting of PIM1 disrupts mTOR signaling and mitochondrial metabolism in IDH1-mutant glioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract DDDR-11
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
From idea to impact: NCI funding for early-stage startups developing neuro-oncology technologies
Exhibit Hall D & E, Second Floor, Convention Center · Abstract EXTH-64
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Longitudinal single-cell immune profiling of cerebrospinal fluid in recurrent IDH-mutant glioma receiving immune checkpoint inhibitor
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMIC-15
Tumor biology
Talk
Sat Nov 14
11:39–11:42am
Phase I/II study of zotiraciclib for recurrent malignant gliomas with IDH mutations: updated results of the phase I study
Exhibit Hall D & E, Second Floor, Convention Center · Abstract CTNI-10
Trials
Talk
Sat Nov 14
12:15–12:18pm
PRISM: Parallel Raman Imaging with Spatial transcriptome and Multi-modal optical imaging of glioma tissue
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMET-06
Tumor biology
Talk
Sun Nov 15
11:14–11:21am
Government agencies
The U.S. government’s medical research agency, supporting biomedical research including cancer and brain tumor studies.
Talk
Fri Nov 13
12:12–12:15pm
Integrated stress response in temozolomide resistant glioblastoma is mediated by deubiquitinase USP8
Exhibit Hall D & E, Second Floor, Convention Center · Abstract CSIG-19
Tumor biology
Talk
Fri Nov 13
12:18–12:21pm
MTAP Loss Enhances PRMT5 Inhibition-Induced BCL-xL/BCL-2-Dependent Apoptotic and Ferroptotic Vulnerabilities in Glioblastoma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract EXTH-01
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Raman-Based Molecular Fingerprinting of Live Cells Using Machine Learning
Exhibit Hall D & E, Second Floor, Convention Center · Abstract BIOM-18
Biomarkers
Poster
Fri Nov 13
7:30–9:30pm
Poster
Fri Nov 13
7:30–9:30pm
Primary Cilia Regulate Glioblastoma-Derived Immunosuppression via an ICAM-1/IL-6 Axis Independent of PD-L1
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMIC-13
Tumor biology
Talk
Sat Nov 14
2:30–3:30pm
◆Platinum Supporter
Foundations & societiesPlatinum Supporter
A nonprofit that funds brain tumor research and advocates for people affected by brain tumors.
Session
Thu Nov 12
11:05am–1:50pm
Session
Thu Nov 12
4:30–5:35pm
Poster
Fri Nov 13
7:30–9:30pm
National Brain Tumor Society (NBTS) Brain Tumor Research Advocate (BTRA) Program
Exhibit Hall D & E, Second Floor, Convention Center · Abstract QLTI-12
Health equity
Foundations & societies
A professional society advancing neuro-oncology research, education, and care.
Talk
Thu Nov 12
2–3:30pm
Session
Fri Nov 13
8:30–10am
Plenary I
Exhibit Hall C, Second Floor, Convention Center
Session
Sat Nov 14
8:30–10am
Plenary III
Exhibit Hall C, Second Floor, Convention Center
Foundations & societies
A nonprofit research organization that collects and shares epidemiologic data on brain and central nervous system tumors to support research and public health.
Poster
Fri Nov 13
7:30–9:30pm
Aligning United States cancer registry data with the 2021 World Health Organization’s Classification of Central Nervous System Tumors
Exhibit Hall D & E, Second Floor, Convention Center · Abstract EPID-17
Health equity
Poster
Fri Nov 13
7:30–9:30pm
Incidence and prevalence of mIDH glioma in the US corrected for missing data
Exhibit Hall D & E, Second Floor, Convention Center · Abstract PATH-60
Pathology
Foundations & societies
A nonprofit research and educational institute advancing cancer research, clinical innovation, and access to oncology therapies.
Poster
Fri Nov 13
7:30–9:30pm
The evidence of therapeutic innovation: analysis of pediatric CNS tumor clinical trials
Exhibit Hall D & E, Second Floor, Convention Center · Abstract CTP-07
Trials · Pediatrics
Government agencies
A National Cancer Center unit that supports early-stage oncology research and clinical trials.
Talk
Fri Nov 13
5:14–5:21pm
IL-7R-LYN Axis Drives Stepwise CNS Infiltration in Acute Lymphoblastic Leukemia
119 AB, First Floor, Convention Center · Abstract CSIG-01
Tumor biology · Lymphoma
Poster
Fri Nov 13
7:30–9:30pm
TF
Tough2gether Foundation
Manhattan, KS
Foundations & societies
A nonprofit supporting families affected by diffuse midline glioma through education, resources, and research.
Poster
Fri Nov 13
7:30–9:30pm
A Patient and Family Reported Outcomes Platform for DMG: Rationale, Design, and Alignment with Existing Clinical Infrastructure
Exhibit Hall D & E, Second Floor, Convention Center · Abstract NCOG-56
Survivorship
Poster
Fri Nov 13
7:30–9:30pm

Explore the full SNO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Philadelphia. Leave your work email and we’ll be in touch.

Privacy

Download the full SNO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from agencies, foundations and societies

Tell us what you sell and we’ll find the people at these agencies, foundations and societies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse SNO 2026 by

Not affiliated with or endorsed by the Society for Neuro-Oncology. Submit a correction